论文部分内容阅读
目的:探讨雷公藤多苷联合贝那普利应用于免疫球蛋白LGA肾病治疗中的可行性。方法:选取2010年10月-2014年12月我院收治的免疫球蛋白LGA肾病患者180例,按照治疗方式的不同分为对照组和观察组,每组患者90例。对照组患者使用雷公藤多苷进行治疗,观察组患者在对照组治疗的基础上加用贝那普利进行治疗,观察治疗后两组患者24小时尿蛋白情况,比较两组患者治疗的总有效率。结果:经过治疗后,对照组患者治疗的总有效率为77.78%;观察组患者治疗的总有效率为94.44%,P<0.05,具有显著性差异和统计学意义。在尿蛋白情况方面,观察组患者明显低于对照组患者,P<0.05,具有显著性差异和统计学意义。结论:雷公藤多苷联合贝那普利应用于免疫球蛋白LGA肾病的治疗中能够有效降低尿蛋白水平,提高治疗的总有效率,在临床中具有较高的可行性。
Objective: To investigate the feasibility of applying tripterygium glycosides combined with benazepril in the treatment of immunoglobulin LGA nephropathy. Methods: 180 cases of immunoglobulin LGA nephropathy admitted in our hospital from October 2010 to December 2014 were divided into control group and observation group according to different treatment methods, 90 cases in each group. Patients in the control group were treated with tripterygium glycosides. Patients in the observation group were treated with benazepril on the basis of the treatment of the control group. The 24-hour urinary protein level in the two groups was observed. The patients in both groups were treated for a total of effectiveness. Results: After treatment, the total effective rate of the control group was 77.78%. The total effective rate of the observation group was 94.44%, P <0.05, with significant difference and statistical significance. Urine protein in the observation group was significantly lower than the control group patients, P <0.05, with significant differences and statistical significance. Conclusion: Tripterygium glycosides combined with benazepril in the treatment of immunoglobulin LGA nephropathy can effectively reduce urinary protein levels and improve the total effective rate of treatment, which has high feasibility in clinical practice.